Compounded GLP-1 in 2026: What Patients Should Know After the Shortage

That does not mean compounded GLP-1 medications suddenly became illegal when the shortages ended. Instead, the rules around when and how they may be prepared have changed.

During the shortage, compounding played an important role in expanding access when demand for medications such as Wegovy, Ozempic, Zepbound, and Mounjaro exceeded supply. Today, compounded semaglutide and tirzepatide remain part of the GLP-1 landscape, but access is increasingly based on an individual patient's medical needs rather than the broad shortage-era pathway.

For patients paying out of pocket, people whose insurance does not cover weight-loss medication, and international students or newcomers who are unfamiliar with the U.S. healthcare system, understanding these changes can make the process much easier.

Why Did Compounded GLP-1 Medications Become So Common?

Demand for GLP-1 medications increased rapidly over the past several years. At different points, manufacturers had difficulty keeping up with demand, and several GLP-1 products appeared on the FDA Drug Shortage List. That created an important role for compounding pharmacies.

Compounding pharmacies prepare medications differently from manufacturers producing mass-market branded drugs. Depending on the type of pharmacy and the applicable rules, compounded medications can be prepared based on prescriptions and individual patient needs.

Compounded products also should not be described as FDA-approved "generic Ozempic" or "generic Zepbound." Generic drugs go through an FDA approval process; compounded medications operate under a different regulatory framework.

That distinction does not mean compounding has no role. It simply means patients should understand exactly what type of medication they are receiving and where it comes from.

What Changed When the GLP-1 Shortages Ended?

The FDA determined that the shortage of tirzepatide injection was resolved on December 19, 2024, and that the semaglutide injection shortage was resolved on February 21, 2025. Temporary enforcement policies that had allowed broader shortage-related compounding ended during 2025.

This is the biggest reason the compounded GLP-1 market looks different in 2026. During a shortage, federal law provides more flexibility for certain pharmacies and outsourcing facilities to compound medications that may otherwise closely resemble commercially available drugs. Once that shortage ends, the rules become more restrictive. But the key point for patients is: the end of the shortage did not end drug compounding. It changed the circumstances under which compounded GLP-1 medications can be prepared.

For traditional compounding under Section 503A, for example, the medication generally must be prepared based on a prescription for an individual patient. FDA rules also restrict pharmacies from regularly making large quantities of products that are essentially copies of commercially available medications.

An important exception can apply when a prescriber determines and documents that a change in the compounded medication produces a significant difference for an identified individual patient. In other words, the post-shortage model is much more focused on patient-specific prescribing.

Can You Still Get Compounded Semaglutide or Tirzepatide in 2026?

Potentially, yes, but it is no longer simply a matter of choosing compounded medication because the branded medication is unavailable nationwide. A licensed medical professional needs to evaluate the patient and determine the appropriate treatment.

Depending on the individual situation, a prescriber may consider factors such as:

• medical history
• previous experience with GLP-1 treatment
• dosing needs
• formulation
• ingredients or excipients
• tolerability
• other medications
• whether a commercially available medication can appropriately meet that patient's medical needs

A customized dose or formulation may sometimes be relevant, but simply requesting a different dose does not automatically mean a compounded prescription meets regulatory requirements. The clinical reasoning belongs with the prescribing professional.

This is why a legitimate telehealth process should begin with a medical evaluation, rather than simply allowing someone to select a vial and check out online.

Why Are Compounded GLP-1s Still Widely Available Online?

The GLP-1 shortage helped create a large telehealth and pharmacy infrastructure around weight-management treatment. Even after the shortage ended, many of those services did not disappear. Instead, the market has been shifting toward a more individualized model involving:

Patient → licensed healthcare provider → prescription → licensed pharmacy

That distinction is important. The issue in 2026 is not simply whether a website offers compounded GLP-1 medication. Patients should look at how the service works. For example: Does a licensed healthcare professional actually review your health information? Is a prescription required? Can you ask a clinician questions about side effects or dosing? Does the medication come from an identifiable licensed pharmacy? Does the label clearly tell you what medication and concentration you received? These are much more useful questions than simply asking whether a service offers compounded semaglutide.

The FDA has also increased scrutiny of how telehealth companies advertise compounded GLP-1 medications. In March 2026, the agency issued warning letters to 30 telehealth companies, focusing in part on marketing that implied compounded medications were the same as FDA-approved products or failed to clearly explain where the medication was compounded. For patients, the takeaway is relatively simple: look for transparency, not exaggerated claims.

Compounded Does Not Mean the Same Thing as FDA-Approved

This is one distinction worth understanding before starting treatment.

FDA-approved medications go through the FDA's premarket review process for safety, effectiveness, quality, manufacturing, and labeling.

Compounded medications do not go through that same premarket approval process. Instead, compounding pharmacies and outsourcing facilities operate under separate federal and state regulatory requirements.

For patients, that makes the quality of the treatment process especially important.

Before starting a compounded GLP-1, you should understand:

• who prescribed it
• which pharmacy prepared it
• whether it contains semaglutide or tirzepatide
• the concentration of the medication
• your prescribed dose
• how much medication you should inject
• how often you should take it
• who to contact if you have side effects or dosing questions

This is particularly important with compounded injectable GLP-1s because different pharmacies may use different concentrations or vial sizes.

For example, your prescription may be written in milligrams, while a syringe is marked in units or milliliters. FDA has received reports of dosing errors involving compounded injectable semaglutide, including cases where patients measured the wrong amount or dosing calculations were misunderstood.

That does not mean compounded injections should be avoided. It means patients should receive clear dosing instructions and know exactly how much medication to use.

What Should International Students and Newcomers to the U.S. Know?

Finding weight-management treatment can be especially confusing if you are new to the American healthcare system.

You may be trying to understand several things at once:

Does my insurance cover GLP-1 medication? Coverage varies significantly. Some health plans cover GLP-1 medications for certain conditions but exclude medications used specifically for weight management. Others may require prior authorization.

What if I am paying without insurance? Patients who do not have coverage can ask about self-pay treatment options. The cost and availability of both branded and compounded medications can vary.

Do I need a primary care doctor first? Not necessarily. Depending on your location and medical situation, telehealth can provide another way to receive an evaluation from a licensed healthcare professional.

Can a doctor in any state prescribe to me? Telehealth rules generally depend on where the patient is physically located during the appointment. Providers need to meet the applicable licensing or telehealth requirements for that state.

Your visa or immigration status does not replace normal medical requirements. International students, recent graduates, and other foreign residents generally still go through the same basic process: medical evaluation, prescription when appropriate, and pharmacy fulfillment.

How Should You Evaluate a Compounded GLP-1 Option?

If you are comparing your options in 2026, try not to begin with: "Which GLP-1 vial should I buy?"

A better starting point is: "Which treatment option makes sense for my health needs?"

The answer may depend on your medical history, previous treatment, insurance coverage, location, available pharmacies, and your clinician's recommendation.

For some patients, an FDA-approved branded medication may be the appropriate choice.

For others, a clinician may determine that a compounded medication is appropriate based on their individual medical needs and the options legally available to them.

Either way, the safest and most useful first step is a real medical evaluation — not choosing a medication based only on an online advertisement.

Explore Your GLP-1 Options with APSU

Navigating GLP-1 medications can be confusing — especially if you are new to the U.S. healthcare system, paying without insurance, or unsure which options may be available to you.

APSU helps you start with an online evaluation by a licensed medical professional and understand the GLP-1 treatment options that may be appropriate based on your health needs and location, including compounded options when clinically appropriate and available.

Start your online consultation with APSU.